ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook.
from RTT - Earnings https://ift.tt/dFHxcVz
via IFTTT
No comments:
Post a Comment